Short answer
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Non-GAAP framework covers organic revenue, adjusted earnings, EBITDA, cash flow and net debt for quarter ended March 31, 2026.
INTEGRA LIFESCIENCES HOLDINGS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Non-GAAP framework covers organic revenue, adjusted earnings, EBITDA, cash flow and net debt for quarter ended March 31, 2026
- Adjustments exclude recurring strategic costs, including acquisitions, restructuring, EU regulation, Boston recall, amortization and impairment charges
- Goodwill impairment reflects tariff-related uncertainty plus quality, operational and supply issues pressuring market capitalization
- Press release includes reconciliations against GAAP for quarters ended March 31, 2026 and 2025
- Forward guidance covers organic revenue and adjusted diluted EPS, without GAAP reconciliation due to uncertainty in adjustments and foreign exchange
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $391.9M, up 2.4% reported and 1.3% organically, indicating modest underlying demand growth
- Adjusted EPS $0.54 versus $0.41, while GAAP loss narrowed to $(0.06) per share from $(0.33)
- Adjusted EBITDA $76.2M, or 19.4% margin versus 16.6%, reflecting improved operating leverage and lower special charges
- Tissue Reconstruction grew 6.4% organically, offsetting Specialty Surgery’s 0.6% organic decline and Instruments’ 7.7% decline
- Full-year revenue guidance reaffirmed at $1.662B–$1.702B; adjusted EPS raised to $2.40–$2.50 from $2.30–$2.40
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other INTEGRA LIFESCIENCES HOLDINGS CORP 8-K filings
Get the next IART 8-K as it lands
Follow IART for push alerts, or ask the research agent what this filing means.